Efficacy Safety and Pharmacokinetics of Rozanolixizumab in Adult Study Participants with Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Brief description of study

The purpose of this study is to see if rozanolixizumab, an investigational (new) drug, is able to prevent the worsening of symptoms of Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis (LGI1 AIE) when used in conjunction with steroids compared to treatment with steroids only.

Interested participants should reach out to CECResearchStudyInfo@nyulangone.org.

Clinical Study Identifier: s22-00047
ClinicalTrials.gov Identifier: NCT04875975
Principal Investigator: Claude Steriade.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.